<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of breast cancer cell lines and patient-derived breast cancer cells, and responsiveness to unacylated ghrelin.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Breast cancer cell line/Patient sample</th><th valign="top">Known mutations</th><th valign="top">Intrinsic subtype</th><th valign="top">Receptor status</th><th valign="top">Responsive to <break/>Unacylated Ghrelin</th></tr></thead><tbody><tr><td valign="top"><bold>Cell line</bold></td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">MCF7</td><td valign="top"><italic>CDKN2A, PIK3CA</italic></td><td valign="top">Luminal A</td><td valign="top">ER+/PR+/HER2-</td><td valign="top">Yes</td></tr><tr><td valign="top">LCC2</td><td valign="top">N/A</td><td valign="top">Luminal A</td><td valign="top">ER+/PR+/HER2-</td><td valign="top">Yes</td></tr><tr><td valign="top">T47D</td><td valign="top"><italic>PIK3CA, TP53</italic></td><td valign="top">Luminal A</td><td valign="top">ER+/PR+/HER2-</td><td valign="top">Yes</td></tr><tr><td valign="top">ZR75</td><td valign="top"><italic>PTEN</italic></td><td valign="top">Luminal B</td><td valign="top">ER+/PR+/HER2+</td><td valign="top">Yes</td></tr><tr><td valign="top">SKBR3</td><td valign="top"><italic>TP53</italic></td><td valign="top">HER2+</td><td valign="top">HER2+</td><td valign="top">Yes</td></tr><tr><td valign="top">MDA-MB-468</td><td valign="top"><italic>PTEN, RB1, SMAD4,</italic> <break/><italic>TP53</italic></td><td valign="top">Basal-like</td><td valign="top">TNBC</td><td valign="top">Yes</td></tr><tr><td valign="top">MDA-MB-157</td><td valign="top"><italic>NF1, TP53</italic></td><td valign="top">Mesenchymal-like</td><td valign="top">TNBC</td><td valign="top">Yes</td></tr><tr><td valign="top">MDA-MB-231</td><td valign="top"><italic>BRAF, KRAS, TP53,</italic> <break/><italic>CDKN2A, NF2</italic></td><td valign="top">Mesenchymal-like</td><td valign="top">TNBC</td><td valign="top">No</td></tr><tr><td valign="top">HS578T</td><td valign="top"><italic>HRAS, TP53</italic></td><td valign="top">Mesenchymal-like</td><td valign="top">TNBC</td><td valign="top">No</td></tr><tr><td valign="top">DU4475</td><td valign="top"><italic>BRAF,APC, MAP2K4,</italic> <break/><italic>RB1</italic></td><td valign="top">Basal-like</td><td valign="top">TNBC</td><td valign="top">No</td></tr><tr><td valign="top"><bold>Patient samples</bold></td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">ER+ Case 1</td><td valign="top">N/A</td><td valign="top">Luminal A</td><td valign="top">ER+</td><td valign="top">Yes</td></tr><tr><td valign="top">ER+ Case 2</td><td valign="top">N/A</td><td valign="top">Luminal A</td><td valign="top">ER+</td><td valign="top">Yes</td></tr><tr><td valign="top">2147-TG5</td><td valign="top">N/A</td><td valign="top">Basal-like</td><td valign="top">TNBC</td><td valign="top">Yes</td></tr><tr><td valign="top">4013-TG3</td><td valign="top">N/A</td><td valign="top">Basal-like</td><td valign="top">TNBC</td><td valign="top">Yes</td></tr><tr><td valign="top">3887-TG7</td><td valign="top">N/A</td><td valign="top">Mesenchymal-like</td><td valign="top">TNBC</td><td valign="top">No</td></tr><tr><td valign="top">3204-TG6</td><td valign="top">N/A</td><td valign="top">Mesenchymal-like</td><td valign="top">TNBC</td><td valign="top">No</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; N/A: not available.</p></fn></table-wrap-foot></table-wrap>